AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Industrial Minerals Ltd

0.125

+0.0054.17%

Volume:5.00K

Turnover:625.00

Market Cap:10.04M

PE:-4.18

High:0.125

Open:0.125

Low:0.125

Close:0.120

52wk High:0.230

52wk Low:0.100

Shares:80.32M

Float Shares:42.54M

Volume Ratio:0.06

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.030

EPS(LYR):-0.030

ROE:-81.99%

ROA:-44.01%

PB:3.43

PE(LYR):-4.18

Loading ...

Overview Company News Filings

Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF

Taiwan FDA OKs Heron Neutron Medical IND Application for Imaging Drug

MT Newswires Live

Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development

Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002

Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs

Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease

GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy

Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes

ASG Receives U.S. FDA IND Approval to Initiate Phase 1 Clinical Trial of the Lead Drug Beta1 for Male Erectile Dysfunction

Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma

XPOVIO® Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma

Andika Rama Makes Triumphant Comeback to Win TGR Asia Esports GT Championship 2025 as Indonesia Clinches Country Title

Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy

Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs

Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development

Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development

Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025

Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IND.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IND.AU\",,,,,undefined,":{"symbol":"IND.AU","market":"AU","secType":"STK","nameCN":"Industrial Minerals Ltd","latestPrice":0.125,"timestamp":1771909920000,"preClose":0.12,"halted":0,"volume":5000,"delay":0,"changeRate":0.041666666666666706,"nameEN":"Industrial Minerals Ltd","floatShares":42536073,"shares":80322500,"eps":-0.029899,"marketStatus":"Not Yet Opened","change":0.005,"latestTime":"02-24 16:12:00 AEDT","open":0.125,"high":0.125,"low":0.125,"amount":625,"amplitude":0,"askPrice":0.14,"askSize":40000,"bidPrice":0.125,"bidSize":45000,"shortable":3,"etf":0,"ttmEps":-0.029899,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1771974000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.12,"openAndCloseTimeList":[[1771887600000,1771909200000]],"volumeRatio":0.061157,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IND.AU\",,,,,undefined,":{"symbol":"IND.AU","floatShares":42536073,"roa":"-44.01%","roe":"-81.99%","lyrEps":-0.02987,"volumeRatio":0.061157,"shares":80322500,"dividePrice":0,"high":0.125,"amplitude":0,"preClose":0.12,"low":0.125,"week52Low":0.1,"pbRate":"3.43","psRate":"11995.59","week52High":0.23,"institutionHeld":0,"latestPrice":0.125,"committee":0.058824,"eps":-0.029899,"divideRate":0,"volume":5000,"delay":0,"ttmEps":-0.029899,"open":0.125,"prevYearClose":0.13,"prevWeekClose":0.11,"prevMonthClose":0.12,"prevQuarterClose":0.13,"fiveDayClose":0.125,"twentyDayClose":0.125,"sixtyDayClose":0.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610990397","title":"Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF","url":"https://stock-news.laohu8.com/highlight/detail?id=2610990397","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610990397?lang=en_us&edition=fundamental","pubTime":"2026-02-12 12:18","pubTimestamp":1770869880,"startTime":"0","endTime":"0","summary":"SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd.  today announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for AK3280, a novel anti-fibrotic therapy for the treatment of idiopathic pulmonary fibrosis . This clearance enables ArkBio to initiate a Phase 2 proof-of-concept  clinical trial of AK3280 in the United States.The Phase 2 study is a multi-center, randomized, partially double-blind, placebo- and active-controlled trial designed to evaluate the efficacy, safety, and pharmacokinetics of oral AK3280 in patients with IPF. Authorization to proceed with a U.S. Phase 2 study represents a significant milestone in the global clinical development of AK3280.","market":"us","thumbnail":"https://mma.prnewswire.com/media/2516404/ArkBio_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2516404/ArkBio_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/novel-anti-fibrotic-drug-ak3280-cleared-by-fda-to-initiate-phase-2-proof-of-concept-clinical-trial-in-ipf-302685900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FVC","BK7095","IND","IND.AU"],"gpt_icon":0},{"id":"2610604468","title":"Taiwan FDA OKs Heron Neutron Medical IND Application for Imaging Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2610604468","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610604468?lang=en_us&edition=fundamental","pubTime":"2026-02-11 12:03","pubTimestamp":1770782583,"startTime":"0","endTime":"0","summary":"Heron Neutron Medical  said Taiwan's Food and Drug Administration has in-principle approved its resubmitted investigational new drug  application for F18 FBPA Injection, according to a Tuesday Taiwan Exchange filing.Shares gained about 3% in Wednesday's late morning trade.F18 FBPA is an imaging drug used in PET/CT scans to check tumors and test its safety and effectiveness.The approval allows the company to proceed with Phase I and Phase II academic human clinical trials.The IND was resubmitted on Dec. 8, 2025, and the company received notification of approval on Feb. 10, 2026.Heron said no manufacturer worldwide has obtained regulatory approval for F18 FBPA, making the study a first-in-human trial.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND.AU","IND","BK7095"],"gpt_icon":0},{"id":"2610109677","title":"Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2610109677","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610109677?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:15","pubTimestamp":1770765300,"startTime":"0","endTime":"0","summary":"- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology , ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate  studies.- In NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for 7 days. ASC36 tablets also reduced food intake significantly.- In a head-to-head diet-induced obese  rat model, ASC36 demonstrated approximately 32% and 91% greater relative body weight reduction compared to eloralintide and petrelintide, respectively.- Submission of an Investigational New Drug Application  to the U.S. Food and Drug Administration  for ASC36 oral tablets is expected in the second quarter of 2026.HONG KONG, Feb. 11, 2026 /PRNewswire/ -- Ascletis Pharma Inc.  announces that it has selected ASC36 oral tablets, its first oral amylin receptor peptide agonist, for clinical development. Ascletis expects to submit an Investigational New Drug Application  to the U.S. Food and Drug Admini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-selects-oral-amylin-receptor-peptide-agonist-asc36-for-clinical-development-302683760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK7095","IND.AU"],"gpt_icon":0},{"id":"2604195420","title":"Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2604195420","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604195420?lang=en_us&edition=fundamental","pubTime":"2026-01-20 17:00","pubTimestamp":1768899600,"startTime":"0","endTime":"0","summary":"- In head-to-head non-human primate  studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous  dosing in humans.- ASC37's average in vitro activity was approximately 5-, 4-, and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively.- Submission of an Investigational New Drug Application  to the U.S. Food and Drug Administration  for ASC37 injection is expected in the second quarter of 2026.HONG KONG, Jan. 20, 2026 /PRNewswire/ -- Ascletis Pharma Inc.  announces that it has selected ASC37 injection, a next-generation, once-monthly, subcutaneously administered GLP-1R/GIPR/GCGR[1] triple peptide agonist, as a clinical development candidate. Ascletisexpects to submit an Investigational New Drug Applicationto the U.S. Food and Drug Administrationfor ASC37 injection for the treatment of obesity in the second quarter of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-selects-a-next-generation-once-monthly-subcutaneously-administered-glp-1rgiprgcgr-triple-peptide-agonist-asc37-for-clinical-development-302665199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4144","BK7095","GLP","IND","IND.AU","GIPR","BK4590","BK4160"],"gpt_icon":0},{"id":"2604903587","title":"D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002","url":"https://stock-news.laohu8.com/highlight/detail?id=2604903587","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604903587?lang=en_us&edition=fundamental","pubTime":"2026-01-19 09:00","pubTimestamp":1768784400,"startTime":"0","endTime":"0","summary":"SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- D3 Bio, a global clinicalstage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration  has cleared two Investigational New Drug  applications:. D3S003 — aKRAS G12D inhibitor — enabling the start of a Phase 1 firstinhuman clinical trial.A Phase 2 combination trial evaluating D3S001 , the Company's nextgeneration KRAS G12C inhibitor, in combination with D3S002, a selective oral ERK1/2 inhibitor.D3S003 is an orally bioavailable, allelespecific KRAS G12D inhibitor that targets both the GDPbound  and GTPbound  conformations. Preclinical data demonstrate a differentiated, bestinclass profile with potent antitumor activity, favorable druglike characteristics, and a promising safety margin. With FDA clearance received, D3 Bio will advance D3S003 into a Phase 1 firstinhuman study in patients with advanced solid tumors harboring KRAS G12D mutations.","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2758996/D3_BIO_DeShengJi_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2758996/D3_BIO_DeShengJi_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/d3-bio-receives-us-fda-clearance-for-two-ind-applications-enabling-phase-1-trial-of-d3s003-and-phase-2-combination-study-of-elisrasib-d3s001-with-d3s002-302664023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854104046.USD","LU0724618433.USD","LU1854103824.USD","LU2360107325.USD","LU2298322129.HKD","LU0124384867.USD","IND","IE00BFMHRM44.USD","BK4605","BK4588","BK4141","LU1548497426.USD","LU1861215975.USD","ON","LU1861220033.SGD","BK7095","LU2357305700.SGD","LU1978683503.SGD","LU1720051108.HKD","LU1861219969.SGD","IND.AU","BK4585","LU1861214812.USD","LU0348723411.USD","BK4512","IE00BZ199S13.USD","LU1720051017.SGD","IE00BD6J9T35.USD"],"gpt_icon":0},{"id":"2603400937","title":"Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs","url":"https://stock-news.laohu8.com/highlight/detail?id=2603400937","media":"prnewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603400937?lang=en_us&edition=fundamental","pubTime":"2026-01-16 09:00","pubTimestamp":1768525200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Jan. 16, 2026 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines forautoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plans for its core clinical asset, ATG-022 , as well as R&D progress on ATG-125 , its steric hindrance masking AnTenGager T cell engager  platform, and other key preclinical programs.Advancing clinical development across 1L to 3L gastric cancer: Antengene is currently conducting the Phase I/II CLINCH study and","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-presents-at-jpm-strong-clinical-data-update-and-strategic-focus-on-next-generation-adcs-and-tces-302662555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0683600562.USD","LU1629891620.HKD","IE00BFXG1179.USD","LU0106831901.USD","ORR.AU","LU0943347566.SGD","LU1670627923.USD","LU0820562030.AUD","LU0006306889.USD","CRS.AU","IE0034235295.USD","IE0034235188.USD","LU0417517546.SGD","ORR","IND","LU1244550494.USD","LU2264538146.SGD","LU2746668461.USD","ACR.AU","LU1064131342.USD","IE00BN8TJ469.HKD","LU2023250843.SGD","LU1974910355.USD","LU2430703095.HKD","LU0345770308.USD","LU0345770993.USD","LU0345769631.USD","IE00BHPRN162.USD","CR","LU0251132253.USD","LU0170899867.USD","IE00BKVL7J92.USD","LU2065731478.USD","LU2756315664.SGD","BK4581","LU1084165304.USD","IND.AU","CRS","LU0208291251.USD","LU0787776722.HKD","BK4534","LU0820561818.USD","LU2106854487.HKD","LU0868494617.USD","ACR","BK7508","LU0106261372.USD","LU0211328371.USD","IE00B3S45H60.SGD"],"gpt_icon":0},{"id":"2603620144","title":"Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2603620144","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603620144?lang=en_us&edition=fundamental","pubTime":"2026-01-15 12:11","pubTimestamp":1768450260,"startTime":"0","endTime":"0","summary":"SHANGHAI, Jan. 15, 2026 /PRNewswire/ -- AskBio Inc. , a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration  has accepted its Investigational New Drug  application for AB-1009, an investigational adeno-associated virus  gene therapy being developed for the treatment of late-onset Pompe disease. With this announcement, the AB-1009 program advances to Phase 1/2, and AskBio initiates a clinical trial in the United States to explore the safety of AB-1009. The company anticipates recruiting its first patient in early 2026 [1].In September 2024, Belief BioMed  and AskBio entered astrategic collaboration to explore the potential for new gene therapies [2]. BBM granted AskBio a sublicense to use the proprietary AAV capsid in the AB-1009 program and provided AAV vector production services. Within the collaborative development framework, BBM worked closely with the AskBio team, and its co","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/belief-biomed-congratulates-partner-askbio-on-ind-acceptance-by-fda-for-investigational-gene-therapy-for-late-onset-pompe-disease-302661902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GAA","IND","IND.AU","BLA.AU","BK7095"],"gpt_icon":0},{"id":"2601074758","title":"GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2601074758","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601074758?lang=en_us&edition=fundamental","pubTime":"2026-01-05 12:07","pubTimestamp":1767586020,"startTime":"0","endTime":"0","summary":"HONG KONG, Jan. 5, 2026 /PRNewswire/ -- GenEditBio Limited , a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration  has cleared the company's Investigational New Drug  application to initiate Phase 1/2 CLARITY trial activities for its lead in vivo genome-editing program GEB-101 for TGFBI corneal dystrophy.The Phase 1/2 CLARITY trial will collect initial data on the safety, tolerability and efficacy of GEB-101 in corneal dystrophy patients with TGFBI mutation. The study has a seamless, adaptive, multicenter, sequential design. Trial participants will receive a single intrastromal injection of GEB-101. Patient enrollment is expected to commence in the second quarter of this year after site activation in the U.S.\"GEB-101 is a first-in-class investigational genome-editing therapy for TGFBI corneal dystrophy. Current treatment options are limited and do not address the underlying cause, highlightin","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2854138/GEB_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2854138/GEB_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/geneditbio-receives-fda-clearance-of-ind-application-for-its-lead-in-vivo-genome-editing-program-geb-101-for-tgfbi-corneal-dystrophy-302652326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNP","BK7095","IND.AU","IND"],"gpt_icon":0},{"id":"2601566078","title":"Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2601566078","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601566078?lang=en_us&edition=fundamental","pubTime":"2026-01-05 08:10","pubTimestamp":1767571800,"startTime":"0","endTime":"0","summary":"-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 in participants with diabetes. Enrollment is expected to begin in the first quarter of 2026.-ASC30 demonstrated placebo-adjusted weight loss of 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or overweight, with better gastrointestinal tolerability.No hepatic safety signal was observed.ASC30 was discovered and developed in-house at Ascletis a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-announces-us-fda-ind-clearance-for-13-week-phase-ii-study-of-its-oral-small-molecule-glp-1-asc30-in-participants-with-diabetes-302652108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLP","BK4590","IND","BK7095","IND.AU","BK4144"],"gpt_icon":0},{"id":"2592995009","title":"ASG Receives U.S. FDA IND Approval to Initiate Phase 1 Clinical Trial of the Lead Drug Beta1 for Male Erectile Dysfunction","url":"https://stock-news.laohu8.com/highlight/detail?id=2592995009","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592995009?lang=en_us&edition=fundamental","pubTime":"2025-12-17 11:30","pubTimestamp":1765942200,"startTime":"0","endTime":"0","summary":"TAIPEI, Dec. 17, 2025 /PRNewswire/ -- Asia Scientific Global Inc. , a leader in the research and development of novel inhaled drugs, today announced that its lead product, Beta1, has received Investigational New Drug  application clearance from the U.S. Food and Drug Administration . Beta1 is currently the only inhaled investigational therapy for male erectile dysfunction to have received such approval and prepared to enter clinical trial. The FDA's clearance underscores ASG's capabilities in drug development and manufacturing technologies. ASG plans to initiate a Phase 1 clinical trial in Taiwan in the first half of 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/asg-receives-us-fda-ind-approval-to-initiate-phase-1-clinical-trial-of-the-lead-drug-beta1-for-male-erectile-dysfunction-302642871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","BK7143","ASG.AU","IND","IND.AU","ASG"],"gpt_icon":0},{"id":"2592951573","title":"Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2592951573","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592951573?lang=en_us&edition=fundamental","pubTime":"2025-12-17 09:00","pubTimestamp":1765933200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Dec. 17, 2025 /PRNewswire/ --Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental New Drug Application  for XPOVIO  for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma  after at least 2 lines of systemic therapy, who are ineligible for autologous stem cell transplant.Antengene has also developed AnTenGager, a proprietary T cell engager 2.0 platform featuring \"2+1\" bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-expands-xpovio-indications-in-malaysia-with-approval-in-diffuse-large-b-cell-lymphoma-302643389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","LU2065731478.USD","IE0031619046.USD","IE00B7SZL793.SGD","LU0963586101.USD","CRS.AU","IE00B66KJ199.SGD","BK4006","CRS","IND","IND.AU","BK4187","BK7095"],"gpt_icon":0},{"id":"2588011633","title":"XPOVIO® Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2588011633","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588011633?lang=en_us&edition=fundamental","pubTime":"2025-12-03 17:00","pubTimestamp":1764752400,"startTime":"0","endTime":"0","summary":"- XPOVIO  has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for multiple myeloma  when used together with dexamethasone , and its recent approvals as a monotherapy for relapsed or refractory diffuse large B-cell lymphoma  and as a combination therapy when used together with bortezomib and dexamethasone  for MM patients who received at least one prior therapy.- XPOVIO is the first approved XPO1 inhibitor in Hong Kong. With expanding indications in MM and DLBCL, XPOVIO is set to benefit more patients in Hong Kong.- XPOVIO has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets .Antengene Corporation Limited  is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical t","market":"us","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/xpovio-approved-in-hong-kong-for-two-additional-indications-in-multiple-myeloma-and-diffuse-large-b-cell-lymphoma-302631561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0031619046.USD","IE00B66KJ199.SGD","IND.AU","BK4006","CRS.AU","LU0963586101.USD","IE00B19Z4B17.USD","LU2065731478.USD","IE00B7SZL793.SGD","BK4187","IND","BK7095","CRS"],"gpt_icon":0},{"id":"2588051568","title":"Andika Rama Makes Triumphant Comeback to Win TGR Asia Esports GT Championship 2025 as Indonesia Clinches Country Title","url":"https://stock-news.laohu8.com/highlight/detail?id=2588051568","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588051568?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:38","pubTimestamp":1764686280,"startTime":"0","endTime":"0","summary":"The Indonesian driver previously claimed the TGR Asia Esports GT Championship title in 2023BANGKOK, Dec. 2, 2025 /PRNewswire/ -- The TOYOTA GAZOO Racing  Asia Esports GT Championship 2025 concluded at Toyota Alive Space, Bangkok, where fifteen of Asia's top sim drivers from Indonesia, Malaysia, the Philippines, Singapore, and Thailand competed across three high-intensity races in Gran Turismo 7.The championship kicked off with five striking livery designs, each representing the participating countries, bringing vibrancy and identity to the track.On the podium, Andika Rama , first runner-up Moreno Pratama and second runner-up Chong Kai Chang. In the individual category, Indonesia's Andika Rama claimed the top podium spot with a total of 74 points, demonstrating precision, focus, and adherence to his race strategy. First runner-up Moreno Pratama, also from Indonesia, finished with 62 points, while Malaysia's Chong Kai Chang secured second runner-up with 59 points.","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2836311/image.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2836311/image.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/andika-rama-makes-triumphant-comeback-to-win-tgr-asia-esports-gt-championship-2025-as-indonesia-clinches-country-title-302630549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","SG","BK4209","BK4604","03160","BK7141","BK4555","IND.AU","BK4585","TGR.AU","BK4588","GT","TGR","BK4099","BK7505","BK7095","TM","BK4119"],"gpt_icon":0},{"id":"2588035413","title":"Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588035413","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588035413?lang=en_us&edition=fundamental","pubTime":"2025-12-02 17:00","pubTimestamp":1764666000,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ --Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration  has approved the investigational new drug  application for the Phase Ib/II CLINCH-2 study evaluating ATG-022  in combination with MSD's  anti-PD-1 therapy, KEYTRUDA , as well as ATG-022 in combination with pembrolizumab and chemotherapy.CLINCH-2 is a Phase Ib/II study that will be led by its principal investigator Prof. Lin Shen at Beijing Cancer Hospital, the lead trial center. The study is designed to evaluate two combination regimens in patients with CLDN18.2-positive, HER2-negative, and PD-L1-positive  unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-announces-ind-approval-in-china-for-phase-ibii-study-of-atg-022-cldn18-2-adc-in-combination-with-keytruda-pembrolizumab--chemotherapy-302630014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","IE0031619046.USD","BK4080","ORR.AU","IE00B7SZL793.SGD","IE00B19Z4B17.USD","BK4187","BK7095","IND","PK","CRS.AU","BK4218","CRS","BK4006","IE00B66KJ199.SGD","BK4181","LU0963586101.USD","LU2065731478.USD","IND.AU","ADC.AU","BK4231","ORR"],"gpt_icon":0},{"id":"2587618791","title":"Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2587618791","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587618791?lang=en_us&edition=fundamental","pubTime":"2025-11-30 18:15","pubTimestamp":1764497700,"startTime":"0","endTime":"0","summary":"- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology , ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC formulation, respectively, in head-to-head non-human primate  studies.- ASC37 oral tablets' drug exposure, as measured by the area under curve , was approximately 57-fold of retatrutide's drug exposure in head-to-head NHP studies.- Average observed half-life of ASC37 oral tablets was approximately 56 hours in NHP studies, supporting once daily and less frequent oral dosing.- ASC37 in vitro activity was approximately 5-, 4- and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively.- Submission of an Investigational New Drug Application  to the U.S. Food and Drug Administration  for ASC37 oral tablets is expected in the second quarter of 2026.\"Selection of ASC37, a promising oral GLP-1R/GIPR/GCGR triple peptide agonist,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-selects-its-first-oral-glp-1rgiprgcgr-triple-peptide-agonist-asc37-for-clinical-development-302628540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4160","IND.AU","GLP","BK4144","GIPR","BK7104","IND","AUC.AU","BK4590","BK7095"],"gpt_icon":0},{"id":"2584906256","title":"Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2584906256","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584906256?lang=en_us&edition=fundamental","pubTime":"2025-11-20 10:56","pubTimestamp":1763607360,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Nov. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that at the R&D Day taking place today, it will present the latest data and future plans for three mid/late-stage clinical programs, including ATG-022 , ATG-037 , and ATG-101 . The company will also share the latest progress on ATG-125 :A B7H3 x PD-L1 targeted therapy featuring\"IO + ADC\"dual-effect molecules for the treatment of solid tumors and its AnTenGagerT-cell engager  technology platform which incorporates steric hindrance masking, along with updates on several key preclinical programs.In addition, guest expert Prof. Xin Wang, Chief Physician, Drug Clinical Trial Center, National Cancer Center / Cancer Hospital of the Chinese Academy of Medica","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-hosts-2025-rd-day-showcasing-encouraging-clinical-data-and-solid-progress-with-investigational-programs-302621100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR.AU","BK4110","BK4097","ORR","LU2065732104.USD","IE00B7SZL793.SGD","IE0031619046.USD","IE00B19Z4B17.USD","LU2065731478.USD","BK4161","BK7095","CR","IND.AU","PRGS","BK4187","LU0963586101.USD","BK4006","ACR","IE00B66KJ199.SGD","BK7508","BK7096","CRS.AU","CRS","ACR.AU"],"gpt_icon":0},{"id":"2583841945","title":"Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2583841945","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583841945?lang=en_us&edition=fundamental","pubTime":"2025-11-13 07:30","pubTimestamp":1762990200,"startTime":"0","endTime":"0","summary":"- Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, demonstrated a comparable pharmacokinetic  profile to ASC36 and ASC35 dosed alonein head-to-head non-human primate studies.- ASC36 monotherapy demonstrated approximately 32% greater relative body weight reduction compared to eloralintide monotherapy in a head-to-head diet-induced obese  rat study, while ASC35 monotherapy demonstrated approximately 71% greater relative body weight reduction compared to tirzepatide monotherapy in a head-to-head DIO mouse study.- Co-formulation of ASC36 and ASC35 had excellent chemical and physical stability with no aggregation or precipitation caused by fibrillation at neutral pH.HONG KONG, Nov. 13, 2025 /PRNewswire/ -- Ascletis Pharma Inc.  announces the co-formulation of ASC36, a once-monthlynext-gen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-announces-co-formulation-of-asc36-once-monthly-next-generation-amylin-receptor-agonist-and-asc35-once-monthly-next-generation-glp-1rgipr-dual-agonist-for-clinical-development-302613467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","PK","BK7095","GLP","BK4144","BK4160","BK4590","BK4218","IND.AU","GIPR"],"gpt_icon":0},{"id":"2579598791","title":"Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2579598791","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579598791?lang=en_us&edition=fundamental","pubTime":"2025-10-30 08:10","pubTimestamp":1761783000,"startTime":"0","endTime":"0","summary":"-In head-to-head non-human primate  studies, average observed half-life of ASC36 was approximately 15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous  dosing in humans.-ASC36 demonstrated approximately 91% greater relative body weight reduction compared to petrelintide in a head-to-head diet-induced obese  rat study.-ASC36 has excellent chemical and physical stability with no fibrillation around neutral pH, allowing for co-formulation with other peptides including ASC35, a GLP-1R/GIPR dual agonist.-Submission of an Investigational New Drug Application  for ASC36 tothe U.S. Food and Drug Administration  is expected in the second quarter of 2026.HONG KONG, Oct. 30, 2025 /PRNewswire/ -- Ascletis Pharma Inc.  announces that it has selected ASC36, a once-monthly, potentially best-in-class subcutaneously administered amylinreceptor agonist, as a clinical development candidate. Ascletis expects to submit an Investigational New Drug Application  for ASC36 for th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-selects-a-best-in-class-once-monthly-subcutaneously-administered-amylin-receptor-agonist-asc36-for-clinical-development-302598393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","IND.AU"],"gpt_icon":0},{"id":"2578643636","title":"Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2578643636","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578643636?lang=en_us&edition=fundamental","pubTime":"2025-10-27 09:00","pubTimestamp":1761526800,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Oct. 27, 2025 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the latest preclinical data of ATG-201  were presented in a Poster Presentation at the 2025 American College of Rheumatology  Annual Meeting, taking place from October 24th to October 29th in Chicago, IL, the United States. ATG-201 is a lead program developed using AnTenGager, the company's proprietary T-cell engager  platform which features \"2+1\" bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome  and enhance efficacy.In in vitro studies, ATG-201 demonstrated stronger B cell depletion activity in peripheral blood mononuclear c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-presents-latest-preclinical-data-of-atg-201-cd19-x-cd3-tce-at-acr-2025-302593957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","BK4077","IE00B19Z4B17.USD","BK4187","CRS","LU0963586101.USD","IE00B7SZL793.SGD","BK4006","BK4110","CRS.AU","LU2065731478.USD","ACR","BK4218","BK4181","BK7508","PK","IE0031619046.USD","BK7096","ACR.AU","IE00B66KJ199.SGD","SLE","IND.AU"],"gpt_icon":0},{"id":"2576000976","title":"Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2576000976","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576000976?lang=en_us&edition=fundamental","pubTime":"2025-10-20 09:00","pubTimestamp":1760922000,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Oct. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines forhematologic malignancies and solid tumors, today announced that the latest results from the ongoing Phase I/II CLINCH study of ATG-022 , were presented in a Poster Presentation at the European Society for Medical Oncology Congress 2025  in Berlin, Germany.Details of the Poster Presentation: ATG-022 Title:Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction cancer Abstract Number: 2907Presentation Number: 2113P. ATG-022 is a CLDN18.2-targeted ADC with sub-nM affinity and fast internalization. Using a VC-MMAE linker-payload , ATG-022 has demonstrated potent activity across tumors with high, low, and ultra-low CLDN18.2 expression.AmongGC/GEJC patients with low/ultra low CLDN18.2 expressi","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-presents-latest-atg-022-clinical-data-at-esmo-2025-demonstrating-efficacy-across-all-cldn18-2-expression-levels-and-exceptional-tolerability-302588393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","IE00B19Z4B17.USD","ORR","LU0963586101.USD","CRS","LU2065731478.USD","BK4006","ORR.AU","OS","BK7095","BK4187","CRS.AU","BK4161","IE0031619046.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4097","IND.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}